WAM
AKBA icon

Wealthspire Advisors (Maryland)’s Akebia Therapeutics AKBA Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9
Closed – – 2416
2018
Q1 		$0 Hold
9
– – ﹤0.01% 2482
2017
Q4 		$0 Buy
+9
New +$149 ﹤0.01% 2425

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s AKBA Position: Q2 2018 in Review

Wealthspire Advisors (Maryland) sold out of Akebia Therapeutics (AKBA) in Q2 2018, closing a stake of 9 shares.

Wealthspire Advisors (Maryland) first reported a position in AKBA in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q1 2018. 145 funds tracked by Wall St. Rank hold AKBA as of Q2 2018.

  • Wealthspire Advisors (Maryland) reported no remaining Akebia Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 9 Akebia Therapeutics shares in Q2 2018.
  • Wealthspire Advisors (Maryland) first reported a position in Akebia Therapeutics in Q4 2017 and held it in 2 quarters.
  • Wealthspire Advisors (Maryland)'s Akebia Therapeutics position peaked at $0 in Q1 2018.
  • 145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2018.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2018, filed 8 Aug 2018.